Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Cabinet Approves Health, Medical Strategy
July 24, 2014
- Toshihiko Takeda Appointed Councilor in Charge of Health Insurance
July 24, 2014
- PMDA Reviewing Infliximab for Risk of Rhabdomyolysis
July 24, 2014
- PAFSC’s First Committee to Discuss MSD’s Insomnia Drug on Aug. 1
July 24, 2014
- Ex-Novartis Employee Indicted on Additional Charges, Prosecutors to Wind Up Probe: Reports
July 23, 2014
- Chain Pharmacies’ Drug Price Settlement Rate in June Triples from 2 Years Ago
July 23, 2014
- MHLW FY2015 Budget Request to Center on PM Abe’s Growth Strategy
July 22, 2014
- ICH M7 Guideline Reaches Step 4; MHLW to Issue Notification
July 22, 2014
- Ministry Panel Agrees to Add Kitasato Daiichi Sankyo Vaccine’s Squarekids to Routine Vaccine Program
July 18, 2014
- Post-Shipment Quality Control Testing of Radiopharmaceuticals Would Not Violate GMP: MHLW
July 18, 2014
- Is Legal Regulation Necessary? Clinical Research at Turning Point 2: Prof. Kageyama of Jikei Univ.
July 18, 2014
- MOF Official in Charge of Health Spending to “Carefully” Discuss Budgets
July 17, 2014
- Council OKs Public-Knowledge Based Application for Oxaliplatin at Doses Approved Overseas
July 16, 2014
- 50% Price Rule, Unifying Price Brackets Starters of Next Generic Price Revision Discussions: Ministry Official
July 15, 2014
- MHLW Panel to Elaborate Proposed Scheme to Broaden Drug Development Requests
July 15, 2014
- Editor’s Pick: Five Healthcare News Headlines for June 30 - July 11
July 14, 2014
- Revised PAL to Go Live on November 25: Ministry Exec
July 14, 2014
- Science Ministry’s Updated Guidelines to Require Research Data Preservation
July 14, 2014
- Draft Policy on Resource Allocation Focuses Funding on 9 Fields of Healthcare R&D
July 14, 2014
- Is Legal Regulation Necessary? Clinical Research at Turning Point 1: TRI Director Fukushima
July 14, 2014
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…